DREAMM-11, Part 2: Japanese phase I trial of belantamab mafodotin combination therapies in relapsed/refractory multiple myeloma.

Int J Hematol · 2025 · PMC11782446 · PMID 39718747

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

In DREAMM-8, a statistically significant PFS benefit compared with pomalidomide plus bortezomib and dexamethasone (PVd) as well as a positive trend in OS, and a safety profile that is broadly consistent with the individual agents [ 9 ].

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.